Gut-liver axis: An immune link between celiac disease and primary biliary cirrhosis

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 3, 2013, Pages 253-261

  Volta, Umberto ^a   Caio, Giacomo ^a   Tovoli, Francesco ^a   De Giorgio, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

antimitochondrial antibodies; celiac disease; genetics; gut liver axis; immune response to bacterial and food antigens; intestinal microbiota; intestinal permeability; primary biliary cirrhosis; small bowel and liver biopsy; tissue transglutaminase antibodies

Indexed keywords

AUTOANTIBODY; BACTERIAL ANTIGEN; FOOD ANTIGEN; MITOCHONDRION ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PYRUVATE DEHYDROGENASE;

AUTOIMMUNE DISEASE; CELIAC DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOPATHOLOGY; INTESTINE MUCOSA PERMEABILITY; LIVER INJURY; LYMPHOCYTE HOMING; MALE; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PORTAL VEIN BLOOD FLOW; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; REVIEW; SCREENING TEST; SEX DIFFERENCE; T LYMPHOCYTE;

CELIAC DISEASE; COMORBIDITY; FEMALE; GASTROINTESTINAL TRACT; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; PREVALENCE; T-LYMPHOCYTES;

EID: 84874605846     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.5     Document Type: Review

References (77)

1. Mehal WZ. The gut-liver axis: a busy two-way street. Hepatology 55(6), 1647-1649 (2012).
2. Stevens FM, McLoughlin RM. Is coeliac disease a potentially treatable cause of liver failure? Eur. J. Gastroenterol. Hepatol. 17(10), 1015-1017 (2005).
3. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat. Rev. Immunol. 6(3), 244-251 (2006).
4. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. Clin. Rev. Allergy Immunol. 36(1), 62-70 (2009).
5. Hagander B, Berg NO, Brandt L, Nordén A, Sjölund K, Stenstam M. Hepatic injury in adult coeliac disease. Lancet 2(8032), 270-272 (1977).
6. Lindberg T, Berg NO, Borulf S, Jakobsson I. Liver damage in coeliac disease or other food intolerance in childhood. Lancet 1(8060), 390-391 (1978).
7. Fausa O, Elgjo K, Schrumpf E. Hepatic lesions in adult coeliac disease. Scand. J. Gastroenterol. 25(7), 656-662 (1990).
8. Volta U, De Franceschi L, Molinaro N et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig. Dis. Sci. 43(10), 2190-2195 (1998).
9. Volta U, Rodrigo L, Granito A et al. Celiac disease in autoimmune cholestatic liver disorders. Am. J. Gastroenterol. 97(10), 2609-2613 (2002).
10. Villalta D, Girolami D, Bidoli E et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J. Clin. Lab. Anal. 19(1), 6-10 (2005).
11. Duggan JM, Duggan AE. Systematic review: the liver in coeliac disease. Aliment. Pharmacol. Ther. 21(5), 515-518 (2005).
12. Volta U, Villanacci V. Celiac disease: diagnostic criteria in progress. Cell. Mol. Immunol. 8(2), 96-102 (2011).
13. Guandalini S, Ventura A, Ansaldi N et al. Diagnosis of coeliac disease: time for a change? Arch. Dis. Child. 64(9), 1320-1324 (1989).
14. Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann. Intern. Med. 142(4), 289-298 (2005).
15. Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3(7), 797-801 (1997).
16. Mäki M, Mustalahti K, Kokkonen J et al. Prevalence of celiac disease among children in Finland. N. Engl. J. Med. 348(25), 2517-2524 (2003).
17. Mustalahti K, Catassi C, Reunanen A et al.; Coeliac EU Cluster, Project Epidemiology. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann. Med. 42(8), 587-595 (2010).
18. Karell K, Louka AS, Moodie SJ et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum. Immunol. 64(4), 469-477 (2003).
19. Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 119(1), 234-242 (2000).
20. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 373(9673), 1480-1493 (2009).
21. Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. Am. J. Med. 123(8), 691-693 (2010).
22. Basso D, Guariso G, Fogar P et al. Antibodies against synthetic deamidated gliadin peptides for celiac disease diagnosis and follow-up in children. Clin. Chem. 55(1), 150-157 (2009).
23. Mozo L, Gómez J, Escanlar E, Bousoño C, Gutiérrez C. Diagnostic value of antideamidated gliadin peptide IgG antibodies for celiac disease in children and IgAdeficient patients. J. Pediatr. Gastroenterol. Nutr. 55(1), 50-55 (2012).
24. Husby S, Koletzko S, Korponay-Szabó IR et al.; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr. 54(1), 136-160 (2012).
25. Martucci S, Corazza GR. Spreading and focusing of gluten epitopes in celiac disease. Gastroenterology 122(7), 2072-2075 (2002).
26. Volta U, Ballardini G, Molinaro N, De Franceschi L, Groff P, Bianchi FB. Specific reactivity of fluorescein isothiocyanateconjugated separated IgG and IgA from celiac disease sera on human tissues. Int. J. Clin. Lab. Res. 25(2), 110-115 (1995).
27. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 377(9777), 1600-1609 (2011).
28. Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin. Liver Dis. 12(2), 261-276 (2008).
29. Berg PA, Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig. Dis. 10(2), 85-101 (1992).
30. Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc. Natl Acad. Sci. USA 85(22), 8654-8658 (1988).
31. Muratori P, Muratori L, Gershwin ME et al. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin. Exp. Immunol. 135(1), 154-158 (2004).
32. Oertelt S, Rieger R, Selmi C et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMAnegative primary biliary cirrhosis. Hepatology 45(3), 659-665 (2007).
33. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis. 25(3), 298-310 (2005).
34. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45(1), 118-127 (2007).
35. Kim WR, Lindor KD, Locke GR 3rd et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119(6), 1631-1636 (2000).
36. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 127(2), 470-475 (2004).
37. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53(6), 865-870 (2004).
38. Leslie WD, Bernstein CN, Leboff MS; American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125(3), 941-966 (2003).
39. Allocca M, Crosignani A, Gritti A et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55(12), 1795-1800 (2006).
40. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 50(1), 291-308 (2009).
41. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31(4), 1005-1013 (2000).
42. Scheuer P. Primary biliary cirrhosis. Proc. R. Soc. Med. 60(12), 1257-1260 (1967).
43. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch. A. Pathol. Anat. Histol. 379(2), 103-112 (1978).
44. Padgett KA, Selmi C, Kenny TP et al. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J. Autoimmun. 24(3), 209-219 (2005).
45. Rigamonti C, Shand LM, Feudjo M et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55(3), 388-394 (2006).
46. European Association for the Study of the Liver. EASL. Clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51(2), 237-267 (2009).
47. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr. Opin. Gastroenterol. 27(3), 285-288 (2011).
48. Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J. Clin. Gastroenterol. 25(1), 328-329 (1997).
49. Bardella MT, Quatrini M, Zuin M et al. Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am. J. Gastroenterol. 92(9), 1524-1526 (1997).
50. Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 42(1), 120-122 (1998).
51. Niveloni S, Dezi R, Pedreira S et al. Gluten sensitivity in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 93(3), 404-408 (1998).
52. Sorensen HT, Thulstrup AM, Blomqvist P, Nørgaard B, Fonager K, Ekbom A. Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data. Gut 44(5), 736-738 (1999).
53. Gillett HR, Cauch-Dudek K, Jenny E, Heathcote EJ, Freeman HJ. Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. Can. J. Gastroenterol. 14(8), 672-675 (2000).
54. Floreani A, Betterle C, Baragiotta A et al. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig. Liver Dis. 34(4), 258-261 (2002).
55. Chatzicostas C, Roussomoustakaki M, Drygiannakis D et al. Primary biliary cirrhosis and autoimmune cholangitis are not associated with coeliac disease in Crete. BMC Gastroenterol. 2, 5(2002).
56. Habior A, Lewartowska A, Orlowska J et al. Association of coeliac disease with primary biliary cirrhosis in Poland. Eur. J. Gastroenterol. Hepatol. 15(2), 159-164 (2003).
57. Oberhüber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 11(10), 1185-1194 (1999).
58. Bizzaro N, Villalta D, Tonutti E et al. IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig. Dis. Sci. 48(12), 2360-2365 (2003).
59. Bizzaro N, Tampoia M, Villalta D et al. Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis. J. Clin. Lab. Anal. 20(5), 184-189 (2006).
60. Zanoni G, Navone R, Lunardi C et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. 3(9), e358 (2006).
61. Stene LC, Honeyman MC, Hoffenberg EJ et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am. J. Gastroenterol. 101(10), 2333-2340 (2006).
62. Selmi C, Balkwill DL, Invernizzi P et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 38(5), 1250-1257 (2003).
63. Selmi C, Gershwin ME. Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr. Opin. Rheumatol. 16(4), 406-410 (2004).
64. Bogdanos DP, Vergani D. Bacteria and primary biliary cirrhosis. Clin. Rev. Allergy Immunol. 36(1), 30-39 (2009).
65. Berg CP, Kannan TR, Klein R et al. Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int. 29(6), 797-809 (2009).
66. Abenavoli L, Arena V, Giancotti F, Vecchio FM, Abenavoli S. Celiac disease, primary biliary cirrhosis and Helicobacter pylori infection: one link for three diseases. Int. J. Immunopathol. Pharmacol. 23(4), 1261-1265 (2010).
67. Sanz Y, De Pama G, Laparra M. Unraveling the ties between celiac disease and intestinal microbiota. Int. Rev. Immunol. 30(4), 207-218 (2011).
68. Corazza G, Valentini RA, Frisoni M et al. Gliadin immune reactivity is associated with overt and latent enteropathy in relatives of celiac patients. Gastroenterology 103(5), 1517-1522 (1992).
69. Book L, Zone JJ, Neuhausen SL. Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am. J. Gastroenterol. 98(2), 377-381 (2003).
70. Hirschfield GM, Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 360(24), 2544-2555 (2009).
71. Liu X, Invernizzi P, Lu Y et al. Genomewide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat. Genet. 42(8), 658-660 (2010).
72. Liu Y, Helms C, Liao W et al. A genomewide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4(3), e1000041 (2008).
73. Plaza-Izurieta L, Castellanos-Rubio A, Irastorza I, Fernández- Jimenez N, Gutierrez G, Bilbao JR; CEGEC. Revisiting genome wide association studies (GWAS) in coeliac disease: replication study in Spanish population and expression analysis of candidate genes. J. Med. Genet. 48(7), 493-496 (2011).
74. Zhernakova A, Stahl EA, Trynka G et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 7(2), e1002004 (2011).
75. Trynka G, Wijmenga C, van Heel DA. A genetic perspective on coeliac disease. Trends Mol. Med. 16(11), 537-550 (2010).
76. Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol. Res. doi:10.1111/j.1872-034X.2012.01088 (2012) (Epub ahead of print).
77. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 13(9), 1236-1245 (2007).